Creative Biolabs
Provides custom 3D bio-printed tissue models and iPSC services for drug discovery and preclinical testing, mimicking complex organ structures like the liver and cardiovascular system.
- CEO / Founder
- Jing Zhang
- Team Size
- 51-200
- Stage
- Active
- Latest Round
- Bootstrapped
Technology & Products
Key Products
Creative Biolabs provides custom biotechnology and pharmaceutical services, including 3D bio-printed tissue models, iPSC services, and antibody production and engineering for drug discovery and preclinical testing.
Technological Advantage
Proprietary integration of multiple bioprinting modalities with iPSC reprogramming and antibody engineering to create physiologically relevant disease models; supported by over a decade of drug R&D experience.
Differentiation
Value Proposition
Reduces drug development costs and supports the 3Rs principle by providing high-fidelity in vitro 3D bio-printed tissue models for more accurate toxicity and efficacy screening compared to 2D cultures.
How They Differentiate
Unlike hardware-focused bioprinting firms, Creative Biolabs operates as a full-service CRO, combining 3D tissue fabrication with downstream drug screening, pharmacodynamics, and ADME/toxicity testing.
Market & Competition
Target Customers
Biotechnology, pharmaceutical, and diagnostic industries
Industry Verticals
Medical; Biotechnology; Pharmaceutical; Diagnostics
Competitors
Creative Diagnostics, Creative Biostructure, Bethyl Laboratories, RayBiotech
Growth & Milestones
Growth Metrics
Estimated annual revenue of $4M; 290+ citations in peer-reviewed publications and patents; expanded iPSC and astrocyte differentiation platforms in 2024.
Major Milestones
Established 3D bio-printed tissue/organ-on-a-chip models; Developed Phage Display and Membrane Protein platforms; Launched non-GMP antibody production platform; Participated in PEGS Summit Boston 2024
Notable Customers
Biogen; University of Zurich